We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
单次剂量的CRISPR疗法NTLA-2002在III期试验中将遗传性血管性水肿发作减少87%。了解这将如何改变治疗并铺平治愈之路。
